Prazertx
6 known investors
Prazer Therapeutics develops therapeutics using Targeted Protein Degradation (TPD) technology, including its SPiDEM platform, in which small molecules selectively bind pathological proteins and activate the ubiquitin-proteasome system for their elimination. The company's pipeline focuses on treatments for viral infections and associated diseases as well as other refractory conditions.
Also known as Prazer Β· Prazer Therapeutics Β· Prazer Therapeutics Inc. Β· νλ μ΄μ ν λΌν¨ν±μ€
Investors Β· 6
Also in the syndicate Β· 5
Company profile
researched Aug 2026Prazer Therapeutics (νλ μ΄μ ν λΌν¨ν±μ€) is a Seoul-based biotechnology company that designs small-molecule therapeutics based on targeted protein degradation (TPD), a modality that recruits intracellular proteasomal and lysosomal degradation pathways to selectively eliminate disease-causing proteins. Its proprietary platform, SPiDEM, uses small molecules that bind a pathological protein while concurrently activating the ubiquitin-proteasome system, an approach the company frames as making so-called undruggable targets druggable.
The pipeline spans neurodegenerative diseases, cancers and inflammatory diseases, alongside antiviral programs aimed at chronic hepatitis B caused by hepatitis B virus and at acute lung inflammation associated with coronaviruses, influenza viruses and respiratory syncytial virus. The company reports that its SPiDEM-derived candidates have shown improved pharmacokinetics and efficacy and reduced drug resistance relative to existing TPD approaches. Management has stated a goal of entering clinical development in 2027, with programs still at the preclinical stage as of 2025.
Founding story
The company was founded in 2019; its founding team includes Kyung-Soo Inn as founder and chief executive, JungJin Ahn as co-founder and chief financial officer, and Nam-Jung Kim as co-founder and chief scientific officer.
Business model
B2B biotechnology model centred on proprietary drug discovery and platform licensing, including collaboration and license agreements with pharmaceutical partners such as Johnson & Johnson for SPiDEM-based degrader development.
Collaboration, research and license agreements with pharmaceutical partners, complemented by equity financing.
Traction
Closed a Series B in April 2025 with participation from JJDC and eight other investors; signed a joint R&D and license agreement with Johnson & Johnson in January 2026; recognised by KDDF among nine outstanding national drug development projects in December 2025; reported headcount growth from 19 to 25 employees in the quarter to April 2026; completed a pre-IPO financing announced in 2026.
Latest developments
In 2026 the company announced completion of a KRW 50bn pre-IPO investment round that added Silicon Valley venture firm Playground Global as a new investor, following its January 2026 joint research, development and license agreement with Johnson & Johnson on SPiDEM-based degraders for neurodegenerative disease. Management has described the J&J collaboration as an inflection point for its global business development and has said it is pursuing further partnerships in neurodegenerative disease and degrader-antibody conjugates.
βΈFull profile β market position, technology, go-to-market, geography, history
Market position
A Korean TPD-focused biotech positioned among next-generation protein degradation developers; comparable companies cited include Pin Therapeutics, AUTOTAC Bio and Amphista Therapeutics. Its selection by JJDC as the first Korean equity investment by that corporate venture arm was noted as the first big-pharma CVC investment in a Korean biotech since Novartis's CVC backed Pharmabcine 13 years earlier.
The company describes its degraders as distinct from other TPD players that depend on linkers and E3 ligase binders, and reports superior pharmacokinetics, efficacy and reduced drug resistance versus currently available TPD technologies, together with a dual-pathway degradation mechanism.
Technology
SPiDEM is a targeted protein degradation platform in which a small molecule binds a pathological protein and simultaneously activates the ubiquitin-proteasome system, harnessing proteasomal and lysosomal degradation pathways. Company statements describe a dual-pathway TPD approach that differs from conventional degraders relying on linkers and E3 ligase binders, and pair it with rational drug design.
Go-to-market
Partnering and out-licensing with global pharmaceutical companies, pursued through business-development activity at industry venues such as BIO USA, where management has said it is seeking additional neurodegenerative disease and degrader-antibody conjugate (DAC) partnerships.
Pharmaceutical and biotechnology partners for research collaborations and licensing; ultimately patients with refractory diseases including neurodegenerative disorders, cancers, inflammatory conditions and chronic viral infections.
Geography
Headquartered in Seoul, South Korea, with global business development activity including partnering at BIO USA in the United States.
History
Founded in 2019 in Seoul, the company raised Series A financing in December 2020 and March 2021 and closed a KRW 29bn Series B in April 2025 that included Johnson & Johnson's venture arm JJDC. In December 2025 one of its programs was named among nine outstanding projects by Korea's National Drug Development Foundation (KDDF). In January 2026 it signed a joint research, development and license agreement with Johnson & Johnson covering SPiDEM-based degraders for neurodegenerative disease, and in 2026 it announced a KRW 50bn pre-IPO round.
Compiled by commissioned research from 5 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 5
launches, deals, and filingsThe company announced completion of a pre-IPO equity investment totalling KRW 50bn, with Silicon Valley venture firm Playground Global joining as a new investor.
Prazer Therapeutics signed a joint R&D and license agreement with Johnson & Johnson to develop SPiDEM-based targeted protein degraders for neurodegenerative disease.
The Korea Drug Development Fund (KDDF) named Prazer Therapeutics among nine outstanding projects out of 496 at its 2025 outstanding project presentation.
Korean coverage reported that JJDC, Johnson & Johnson's investment arm, selected Prazer Therapeutics as its first equity investment in Korea; the company was described as preclinical with a post-money value of KRW 120bn and a target of entering the clinic in 2027.
Prazer Therapeutics announced completion of a Series B round of approximately KRW 29bn, led with participation from Johnson & Johnson Innovation - JJDC, with proceeds allocated to R&D and global commercialization.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 5
primary sources listed
- Prazertxprazertx.com Β· web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Prazertx do?
- Korean biotech developing targeted protein degradation drugs on its SPiDEM platform for neurodegenerative, viral and other refractory diseases.
- Who are Prazertx's investors?
- Prazertx's investors include Kiwoom Investment.